Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.62), $0.10 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $65 million versus the consensus estimate of $30.92 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westport Fuel Systems (WPRT) Misses Q2 EPS by 64c
- Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c
- Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
